LONDON, ONTARIO--(Marketwired - Oct. 3, 2013) - Critical Outcome Technologies Inc. (TSX VENTURE:COT) ("COTI" or the "Company"), the bioinformatics and accelerated drug discovery company, announced today that Dr. Wayne Danter, President & CEO, will be presenting at the 12th Annual BIO Investor Forum (http://www.bio.org/events/conferences/12th-annual-bio-investor-forum) on Wednesday, October 9, 2013, at 9:30 a.m. PDT in San Francisco.
Dr. Danter will highlight the Company's innovative drug discovery platform technology and two-pronged commercial validation and revenue strategy during the live presentation. Dr. Danter will also be available to participate in one-on-one meetings with investors who are registered to attend the conference.
An online investor kit, including the Company's investor presentation and fact sheet, are available on the Company's corporate blog at http://www.criticaloutcomeblog.com/investor-kit.html.
Follow @CriticalOutcome and the official conference feed on Twitter, and join the conversation by using #BIF13.
About Critical Outcome Technologies Inc. (COTI)
COTI is a leading-edge technology company specializing in accelerating the discovery and development of small molecules - dramatically reducing the time and cost to bring new drugs to market. COTI'S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.
For more information, visit www.criticaloutcome.com.
Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.